Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methyltransferase-like protein 14 (METTL14) is a critical non-catalytic subunit of the N6-methyladenosine (m6A) methyltransferase complex, which also includes the catalytic subunit METTL3 and the regulatory protein WTAP. METTL14 acts as an essential structural scaffold that binds to substrate RNA and stabilizes the complex, facilitating the deposition of m6A modifications on mRNA and non-coding RNAs. This epitranscriptomic modification plays a pivotal role in regulating RNA processing, splicing, stability, and translation, thereby controlling key cellular processes such as stem cell pluripotency, cell differentiation, and immune responses.\n\nIn oncology, METTL14 is frequently dysregulated and can act as either an oncogene or a tumor suppressor depending on the cellular context. It is highly implicated in acute myeloid leukemia (AML), breast cancer, glioblastoma, and colorectal cancer, where it promotes tumor cell proliferation, metastasis, and resistance to therapies like CDK4/6 inhibitors. Furthermore, METTL14 modulates the tumor immune microenvironment by regulating immune checkpoint molecules such as PD-L1, making it a promising target for combination therapies with immune checkpoint inhibitors. Therapeutic strategies targeting METTL14 include small-molecule inhibitors (e.g., WKYMVM), PROTAC degraders (e.g., WD6305), and complex inhibitors (e.g., STM2457, RSM3) that disrupt the METTL3-METTL14 interaction or degrade the complex to suppress oncogenic signaling.
Inhibition of the m6A methyltransferase complex, degradation of the METTL3-METTL14 complex, or disruption of the METTL3-METTL14 interaction
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methyltransferase-like protein 14 (METTL14).